Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-09-26
1998-04-21
Gupta, Yogendra N.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514277, 514345, 514350, 514352, 514354, 546122, 546290, 546300, 546312, 546331, 546333, A61K 31435, C07D48704, C07D21302
Patent
active
057417962
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This invention relates to compounds for inhibiting bone resorption that is mediated by the action of a class of cells known as osteoclasts.
Osteoclasts are multinucleated cells of up to 400 .mu.m in diameter that resorb mineralized tissue, chiefly calcium carbonate and calcium phosphate, in vertebrates. They are actively motile cells that migrate along the surface of bone. They can bind to bone, secrete necessary acids and proteases and thereby cause the actual resorption of mineralized tissue from the bone.
The pharmacologic activity of these compounds is useful in the treatment of mammals, including man.
The current major bone diseases of public concern are osteoporosis, hypercalcemia of malignancy, osteopenia due to bone metastases, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, immobilization-induced osteopenia, and glucocorticoid treatment.
All these conditions are characterized by bone loss, resulting from an imbalance between bone resorption (breakdown) and bone formation, which continues throughout life at the rate of about 14% per year on the average. However, the rate of bone turnover differs from site to site, for example, it is higher in the trabecular bone of the vertebrae and the alveolar bone in the jaws than in the cortices of the long bones. The potential for bone loss is directly related to turnover and can amount to over 5% per year in vertebrae immediately following menopause, a condition which leads to increased fracture risk.
There are currently 20 million people with detectable fractures of the vertebrae due to osteoporosis in the United States. In addition, there are 250,000 hip fractures per year attributed to osteoporosis. This clinical situation is associated with a 12% mortality rate within the first two years, while 30% of the patients require nursing home care after the fracture.
Individuals suffering from all the conditions listed above would benefit from treatment with agents which inhibit bone resorption.
Endothelial cells secrete growth factors that are mitogenic for endothelium and can induce formation of new blood vessels (angiogenesis). Angiogenic stimuli cause the elongation or proliferation of endothelial cells and generation of new vessels.
SUMMARY OF THE INVENTION
The present invention involves a compound of the formula ##STR2## wherein X is selected from the group consisting of ##STR3## Y is selected from the group consisting of C.sub.1-8 alkylene, ##STR4## B is ##STR5## R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently selected from the group consisting of consisting of: compound is ##STR6## wherein R.sup.12 is hydroxy or C.sub.-4 alkyloxy, then X-Y is not NH.sub.2 --(CH.sub.2).sub.2 --NH--CO--, ##STR7## and the pharmaceutically acceptable salts thereof.
In one embodiment is the compound wherein ##STR8## Y is selected from the group consisting of C.sub.1-3 alkylene, ##STR9## R.sup.1 is selected from the group consisting of hydrogen and consisting of
In another embodiment is the compound ##STR10## wherein X is selected from the group consisting of ##STR11## Y is selected from the group consisting of C.sub.1-8 alkylene, ##STR12## B is ##STR13## R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently selected from the group consisting of consisting of:
provided that when the compound is ##STR14## wherein R.sup.12 is hydroxy or C.sub.1-4 alkyloxy, then X-Y is not ##STR15## and the pharmaceutically acceptable salts thereof.
In a class of this embodiment is the compound wherein X is selected from the group consisting of ##STR16## Y is selected from the group consisting of C.sub.1-2 alkylene, --C.tbd.C--, ##STR17## R.sup.1 is selected from the group consisting of hydrogen and consisting of
Examples of this class are compounds selected from the group of: ne, acid, alanine, e, nine, .-alanine, nine, -alanine, alanine t-butyl ester, alanine, (S)-phenylsulfonyl-amino----alanine, ropionic acid, amino!-ethyloxybenzoyl-2(S)-phenylsulfonylamino .beta.-alanine, anine, fonyl
Duggan Mark E.
Hartman George D.
Hoffman William F.
Ihle Nathan C.
Gupta Yogendra N.
Merck & Co. , Inc.
Parr Richard S.
Winokur Melvin
LandOfFree
Pyridyl and naphthyridyl compounds for inhibiting osteoclast-med does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridyl and naphthyridyl compounds for inhibiting osteoclast-med, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridyl and naphthyridyl compounds for inhibiting osteoclast-med will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2057710